| Literature DB >> 34970530 |
Yasmine M Abdel Aziz1, Gehad Lotfy1, Mohamed M Said1, El Sayed H El Ashry2, El Sayed H El Tamany3, Saied M Soliman2, Marwa M Abu-Serie4, Mohamed Teleb5, Sammer Yousuf6, Alexander Dömling7, Luis R Domingo8, Assem Barakat9.
Abstract
The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed that concomitant administration of Bcl2 inhibitors can sensitize the tumor cells and induce apoptosis. In this study, we utilized a rapid synthetic route to synthesize two novel hybrid spirooxindole-based p53-MDM2 inhibitors endowed with Bcl2 signaling attenuation. The adducts mimic the thematic features of the chemically stable potent spiro [3H-indole-3,2'-pyrrolidin]-2(1H)-ones p53-MDM2 inhibitors, while installing a pyrrole ring via a carbonyl spacer inspired by the natural marine or synthetic products that efficiently inhibit Bcl2 family functions. A chemical insight into the two synthesized spirooxindoles including single crystal x-ray diffraction analysis unambiguously confirmed their structures. The synthesized spirooxindoles 2a and 2b were preliminarily tested for cytotoxic activities against normal cells, MDA-MB 231, HepG-2, and Caco-2 via MTT assay. 2b was superior to 5-fluorouracil. Mechanistically, 2b induced apoptosis-dependent anticancer effect (43%) higher than that of 5-fluorouracil (34.95%) in three studied cancer cell lines, activated p53 (47%), downregulated the Bcl2 gene (1.25-fold), and upregulated p21 (2-fold) in the treated cancer cells. Docking simulations declared the possible binding modes of the synthesized compounds within MDM2.Entities:
Keywords: Bcl 2; human homolog of mouse double minute 2 (MDM2); p53; protein–protein interaction (PPI); spirooxindole
Year: 2021 PMID: 34970530 PMCID: PMC8713455 DOI: 10.3389/fchem.2021.735236
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Design of spiro [3H-indole-3-3′-pyrrolidin]-2(1H)-one MDM2 inhibitors and optimization to the chemically stable spiro [3H-indole-3-2′-pyrrolidin]-2(1H)-ones series.
FIGURE 2Design strategy of the target spirooxindoles.
SCHEME 1Synthesis of the spirooxindole derivatives 2a,b.
SCHEME 2Synthesis and plausible mechanism for the desired spirooxindole derivative 2a.
SCHEME 3Synthesis and plausible mechanism for the desired spirooxindole derivative 2b.
FIGURE 3Thermal ellipsoid plots at 30% probability level for 2a (A) and 2b (B).
FIGURE 4Crystal packing diagram of compounds 2a and 2b.
FIGURE 5Hirshfeld analysis of 2b.
The short intermolecular contacts in 2b.
| Contact | Distance | Contact | Distance |
|---|---|---|---|
| O4 … H5A | 1.843 | O5 … H4A | 1.816 |
| O4 … H19 | 2.315 | Cl1 … H4 | 2.755 |
| O2 … H11 | 2.278 | S1 … H3 | 2.842 |
| O5 … H1 | 2.468 | C14 … H17 | 2.668 |
FIGURE 6The possible orientation of the two molecular units as a consequence of the substitutional disorder in 2a.
FIGURE 7Hirshfeld analysis of 2a.
The short intermolecular contacts in 2a.
| Contact | Distance | Contact | Distance |
|---|---|---|---|
| O3 … H2A | 1.913 | N1 … H3A | 2.085 |
| O3 … H41 | 2.587 | N4 … H38 | 2.406 |
| O4 … H12 | 2.467 | Cl1 … O5 | 3.042 |
| O4 … H15 | 2.505 | F2 … H24 | 2.349 |
| O4 … H3 | 2.51 |
FIGURE 8The molecular electrostatic potential (MEP) maps of the studied compounds. The color index from blue to turquoise to yellow to red indicat the more negative electron density.
B3LYP/6-31G(d) reactivity indices, in eV, of AYs 3 and 4, and ethylene derivatives 1a and 1b.
|
|
| ω |
| |
|---|---|---|---|---|
| Ethylene | −4.37 | 3.64 | 2.62 | 2.94 |
| Ethylene | −3.97 | 4.04 | 1.96 | 3.13 |
| AY | −3.34 | 3.29 | 1.70 | 4.13 |
| AY | −3.26 | 3.34 | 1.60 | 4.19 |
SCHEME 432CA reaction of AY 3 with the ethylene derivative 1a. ωB97X-D/6-311G(d,p) relative energies in methanol, with respect to separated reagents, are given in kcal·mol−1
FIGURE 9ωB97X-D/6-311G(d,p) geometry of TSs in methanol. The distances are given in Angstrom.
Cytotoxicity of the spirooxindoles 2a and 2b.
| Compound no | EC100 (µM) Wi-38 | IC50 (µM) | ||
|---|---|---|---|---|
| MDA-MB 231 | HepG-2 | Caco-2 | ||
|
| 0.1166 ± 0.0159 | 0.7424 ± 0.0597 | 33.5660 ± 4.5720 | 6.2330 ± 1.4650 |
|
| 0.2269 ± 0.0124 | 0.0018 ± 0.0004 | 0.0569 ± 0.0020 | 0.0028 ± 0.0020 |
| 5-FU | 0.6013 ± 0.0810 | 7.0500 ± 0.2040 | 4.8290 ± 0.2960 | 1.0480 ± 0.1560 |
Note. *Values are presented as mean ± SEM.
FIGURE 10Morphological alterations of 2a- and 2b-treated MDA-MB 231, HepG-2, and Caco-2 cells.
FIGURE 11Flow charts of annexin-PI analysis of 2a- and 2b-treated MDA-MB 231, HepG-2, and Caco-2 cells compared with 5-fluorouracil (5-FU)-treated cells.
Apoptotic cell population percentages in 2a- and 2b-treated MDA-MB 231, HepG-2, and Caco-2 cells.
| Compound no | Total % of apoptotic population | ||
|---|---|---|---|
| MDA-MB 231 | HepG-2 | Caco-2 | |
| Untreated cells | 0.835 ± 0.1d | 0.605 ± 0.09d | 0.99 ± 0.02d |
|
| 21.805 ± 2.335b | 23.48 ± 1.750c | 23.320 ± 2.99c |
|
| 39.44 ± 0.67a | 43.075 ± 0.6a | 42.095 ± 0.25a |
| 6-FU | 13.02 ± 1.78c | 31.59 ± 1.12b | 34.95 ± 0.28b |
Note. *Values are presented as mean ± SEM. Different letters are significantly different in the same column at p < 0.05.
FIGURE 12p53 immunohistochemical analysis of p53 expression in 2a- and 2b-treated HepG-2 cells. (A) Immunostaining images of p53-treated and untreated cells (magnification ×400) with (B) representative percentages of the positive immunostaining HepG-2 cells. Different letters are significantly different at p < 0.05.
FIGURE 13Change in gene expression of Bcl2 in the treated HepG-2 cells. Different letters are significantly different at p < 0.05.
FIGURE 14Change in gene expression of p21 in the treated HepG-2 cells. Different letters are significantly different at p < 0.05.
FIGURE 15(A) Three-dimensional (3D) binding mode of 2a (cyan sticks), (B) 2D binding mode of 2a, (C) 3D binding mode of 2b (dark pink sticks), (D) 2D binding mode of 2b, (E) overlay of 2a and 2b with the co-crystalized human homolog of mouse double minute 2 (MDM2) inhibitor (green sticks), (F) 2D binding mode of the co-crystalized ligand 6SJ in MDM2 (PBD ID: 5LAW) (Gollner et al., 2016). The Leu26, Trp23, and Phe19 pockets of p53 are indicated as well as the key hydrogen bond interactions with MDM2 Leu54.
In silico predicted physicochemical properties, ADMET, and drug likeness of the spirooxindoline derivatives 2a and 2b.
| Cpd. No | Physiochemical parameters | ADME | Bioavailability and drug likeness | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LogP | M.Wt | HBA | HBD | NROTB | TPSA | S | HIA | PPB | BBB | Caco2 | MDCK | CYP3A4 inhibitor | CYP2D6 inhibitor | Lipiniski | Veber | Muegge | PAINSp | |
|
| 2.95 | 437.89 | 4 | 1 | 3 | 54.34 | 2.83 | 96.83 | 88.01 | 0.999 | 33.25 | 110.95 | Yes | Yes | Yes | Yes | Yes | 0 alerts |
|
| 1.87 | 508.98 | 5 | 1 | 4 | 125.46 | 0.08 | 98.09 | 100 | 0.017 | 19.77 | 3.730 | Yes | Yes | Yes (1 violation) | Yes | Yes | 0 |
Note. Log P: logarithm of compound partition coefficient between n-octanol and water.
M.Wt, molecular weight.
HBA, number of hydrogen bond acceptors.
HBD, number of hydrogen bond donors.
NROTB, number of rotatable bonds.
TPSA, polar surface area. Drug-like TPSA <140–150 A2.
S, aqueous solubility (mg/L).
HIA, human intestinal absorption. HIA values <20% (poorly absorbed), values ≈20–70% (moderately absorbed), and values >70% (well absorbed) (Yee 2011).
PPB, plasma protein binding. PPB values <90% (poorly bound) and values >90% (strongly bound) (https://preadmet.bmdrc.kr/adme/ (accessed August 14, 2020).
BBB, blood–brain barrier penetration. BBB values <0.1 (low CNS absorption), values ≈0.1–2 (medium CNS absorption) and values >2 (high CNS absorption (Ma et al., 2005).
Caco2, permeability through cells derived from human colon adenocarcinoma. PCaco2 values <4 nm/s (low permeability), values ≈4–70 nm/s (medium permeability) and values >70 nm/s (high permeability) (Yamashita et al., 2000; Irvine et al., 1999; and; Yazdanian et al., 1998).
MDCK, permeability through Madin–Darby canine kidney cells. PMDCK values <25 nm/s (low permeability), values ≈25–500 nm/s (medium permeability), and values >500 nm/s (high permeability) (Irvine et al., 1999).
Lipinski rule: log P ≤ 5, M. Wt ≤ 500 Da, HBA ≤ 10 and HBD ≤ 5 (Lipinski et al., 2017).
Veber rule: NROTB ≤ 10 and TPSA ≤ 140 (Veber et al., 2002).
Muegge rule: -2 ≤log P ≤ 5, 200 ≤ M. Wt ≤ 600 Da, TPSA ≤ 150, Num. rings ≤ 7, Num. carbons > 4, Num. heteroatom > 1, NROTB ≤ 15, HBA ≤ 10 and HBD ≤ 5 (Muegge et al., 2011).